Submission supported by previously announced data from Phase 3 MPOWERED™ study NEEDHAM, Mass. , June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and

--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- NEEDHAM, Mass. , May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented

-- New clinical data accepted for oral and e-Poster presentation at   AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting -- NEEDHAM, Mass. , May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage

Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1.9M , a 100% increase over Q4 2020 Achieved payor

- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline - Lead pipeline product Oleogel-S10*(Filsuvez®) under regulatory review in the US and EU - Deal expected to

NEEDHAM, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter

--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was generally consistent with the safety observed in the CHIASMA OPTIMAL trial NEEDHAM, Mass.

--Data supports MYCAPSSA ® as non-inferior to long-acting   injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs-- NEEDHAM, Mass.

-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass. , March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize

Phased launch of MYCAPSSA ® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc.

NEEDHAM, Mass. , March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference , which is being held Tuesday, March 9 th -

Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM , MA , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00

Appointment provides extensive commercial-stage public company financial leadership experience NEEDHAM, Mass. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral

MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA ®   EMA submission for EU marketing approval on track for mid-2021 following positive results of MPOWERED Phase 3 clinical trial NEEDHAM, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc.